Poseida Therapeutics, Inc. (PSTX)
After hours:
Chart Events
Performance Outlook
| Previous Close | 2.0000 |
| Open | 2.0200 |
| Bid | 1.5000 x 1000 |
| Ask | 2.2000 x 800 |
| Day's Range | 1.9300 - 2.2100 |
| 52 Week Range | 1.8200 - 11.1000 |
| Volume | |
| Avg. Volume | 172,539 |
| Market Cap | 134.815M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.3200 |
| Earnings Date | Aug 10, 2022 - Aug 15, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 16.25 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for PSTX
Related Research
- Poseida Therapeutics, Inc.Daily – Vickers Top Insider Picks for 02/17/2022The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.RatingFair ValueEconomic Moat3 months agoArgus Research
- PR Newswire
Poseida Therapeutics Appoints Charles M. Baum, M.D., Ph.D., to Board of Directors
Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced the appointment of Charles M. Baum, M.D., Ph.D., to its Board of Directors, effective May 16, 2022. Additionally, the Company announced the resignation of David Hirsch, M.D., Ph.D., from its Board of Directors, effective May 17, 2022.
- PR Newswire
Poseida Therapeutics Presents Encouraging Preclinical Data Highlighting P-ckit-ALLO1 at the ASGCT 2022 Annual Meeting
Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today will present preclinical data at the American Society of Gene and Cell Therapy (ASGCT) 2022 Annual Meeting highlighting the use of anti-c-kit CAR-T cells as a preconditioning agent to enable hematopoietic stem cell (HSC) transplants. The ASGCT Annual Meeting is being held in Wash
- Simply Wall St.
Earnings Release: Here's Why Analysts Cut Their Poseida Therapeutics, Inc. (NASDAQ:PSTX) Price Target To US$16.25
There's been a notable change in appetite for Poseida Therapeutics, Inc. ( NASDAQ:PSTX ) shares in the week since its...
